+34 679 490 537info@nanbiosis.com

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

  • Scientific Coordinator: Dr. Santi Sala sala@icmab.es
  • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
  • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
  • Phone: +34 935 801 853
  • Fax: +34 935 805 729
  • Web: ICMAB
ICMAB CSIC
Order request

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Professor Jaume Veciana, current director of NANOMOL Group, gathers several laboratories to perform the mission of this facility: the characterization, development and large-scale production ofmolecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure.
This unit is composed of the equipment and the scientific and technical personnel to develop and apply efficient, robust and green technologies based on the use of supercritical fluids (or dense gases), such as compressed CO2. The main activity of this unit is focused on the production of pure micro- and nanoparticulate active therapeutic ingredients and passive or active therapeutic nanoconjugates (vesicles, liposomes, nanosuspensions, micro- and nanostructured polymeric particles), as well as porous matrices of biocompatible polymers for tissue engineering or implants. The unit has also instruments and the necessary know-how to undertake nanostructuring of molecular biomaterials in films and surfaces, with application in the development of new biomedical devices. The facilities are equipped with laboratory and pre-pilot scale plants, high pressure phase analyzers and analytical instrumentation for micro- and nanoparticle physico-chemical characterization (particle size distribution, particle concentration, particle morphology and stability, Z-potential). One of the singularities of this unit is that counts with plants at different scales, from mL to L, which allow process development by QbD and process scale-up.
 
U6. Services & Rates

News U6

16 May

Unit 6 of NANBIOSIS-ICTS Biomaterials processing and Nanostructuring at ICMAB-CSIC received the visit of high school students

A group of 22 students from the high school La Serra (Mollerusa) visited the Biomaterials and Nanostructuring Unit of NANBIOSIS,  at the Institute of Material Science of Barcelona of CSIC. The visit was an activity within the Nanoscience and Nanotechnology festival 10alamenos9  in which ICMAB participates. The students were guided through the labs by Amable Bernabé, technical responsible of U6, who explained them about nanotechnology, NANBIOSIS-ICTS research infrastructure and the different techniques available at “Biomaterials processing and Nanostructuring Unit”.[...]

15 May

NMR signal enhancement of >50 000 times in fast dissolution dynamic nuclear polarization

Jaume Veciana, Scientific Director of NANBIOSIS-ICTS has participated  in the research results published in the journal Chemical Communication, wich reports the synthesis and the study of a novel mixed biradical with BDPA and TEMPO radical units that are covalently bound by an ester group (BDPAesterTEMPO) as a polarizing agent for fast dissolution DNP. The biradical exhibits an extremely high DNP NMR enhancement of >50000 times, which constitutes one of the largest signal enhancements observed so far, to the best of our knowledge. Some of the researchs were made taking advantage of the characterization facilities provided by ICTS NANBIOSIS. For more information: L. F.[...]

11 May

NANOMOL group, coorditator of Unit 6 of NANBIOSIS has authored 26% of the scientific articles of ICMAB in NATURE

The Nature Index takes into account the published scientific articles from 1 February 2016 to 31 January 2017.  This index is elaborated annually based on the affiliations of the authors of scientific articles published in a selection of 68 high-quality journals (http://www.natureindex.com/faq#journals) CSIC appears as the first Spanish research centre in this ranking and occupies position number 38 in the global ranking of 500 research centres worldwide, while ICMAB occupies the first position within the CSIC centre, taking into account the corrected index WFC that shares the work between the different co-authoring institutions and corrects for the overrepresentation of som[...]

23 Apr

NANBIOSIS Scientific Director Dr. Jaume Veciana received a Mention of Honor for his dedication to NANBIOSIS

On April 22, Dr. Jaume Veciana received a Mention of Honor from the current President of Extremadura, Guillermo Fernández Vara, during the celebration of the X Anniversary of the Center for Minimally Invasive Surgery “Jesus Usón” for his commitment, effort and dedication in the creation of the Singular Scientific Technological Infrastructures (ICTS) NANBIOSIS, in collaboration with the Center for Biomedical Research Center in Bioingeneering, Biomaterials and Nanomedicine (CIBER-BBN). Further information:[...]

06 Apr

MATBIO 2017
Materials for Biomedical Applications Scientific School (BIOMAT-2017)

Registration is now open for the Scientific School on Materials for Biomedical Applications (BIOMAT-2017) that will take place on 19th-22nd of June 2017 in the UAB Campus (Barcelona). This school is organized by ICMAB-CSIC and it is included in the Severo Ochoa activities of the Institute. The school is addressed to last year undergraduate, master and PhD students, who are interested in the development of materials for biomedical applications. The aim of the school is to present the design, development and application of new materials for a wide range of biomedical applications. The school includes lectures from international and loca[...]

21 Dec

Validation of a drug for foot ulcers in collaboration with Cuba
Validation of a drug for foot ulcers in collaboration with Cuba

Nanomol, (Unit 6 of NANBIOSIS) has announced in Cuba that the process of clinical validation of a new drug developed and patented in collaboration with Center of Genetic Engineering and Biotechnology of Cuba, integrated in BioCubaFarma, has been initiated. The new drug is designed to improve the healing of foot ulcer in diabetics and could be on the market in five years. The collaboration of the Center for Genetic Engineering and Biotechnology of Cuba with Nanomol, coordinating group of Unit 6 of NANBIOSIS, began in 2010. Cuban researchers had developed an effective product in wound healing in diabetics but t[...]

16 Dec

Lipid-based Nanovesicles for Nanomedicine
Lipid-based Nanovesicles for Nanomedicine

Jaume Veciana and Nora Ventosa, Scientific Directors of Unit 6 of NANBIOSIS together with other researchers from NANOMOL group, coordinator of Unit 6 of NANBIOSIS, has recently published an interesting review article in the journal Chemical Society Reviews. This review presents the large plethora of lipid-based nanovescicles available nowadays, focusing on a new generation of non-liposomal L-NVs and showing their similarities and differences with respect to their ancestors (liposomes). Since the overspread of a nanomaterial to the market is also strongly dependent on the availability of technological-scale preparation methods, it also extensively review the current approaches exploited for L-NV production. T[...]

22 Nov

Extraordinary doctoral award
Extraordinary doctoral award

Ingrid Cabrera, member of the NANOMOL group that coordinates Unit 6 of NANBIOSIS, has obtained the extraordinary doctoral award from the Universitat Autònoma de Barcelona for her thesis “Nanovesicle-bioactive conjugates to be used as nanomedicines, prepared by a one-step scalable method Using CO₂-expanded solvents“. This thesis was directed by Jaume Veciana, Scientific Director of NANBIOSIS and Nora Ventosa, Scientific Director of Unit 6 of NANBIOSIS. The main objectives of the  PhD Thesis of Dr. Ingrid Cabrera were the preparation and study of multifunctional nanovesicle based nanoformulation of alfa-galactosidase for the treatment of Fabry desease as well as of another multifunctiona[...]

Nanbiosis